If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-15. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
== General references == Acheson, D. J. (1990), Elementary Fluid Dynamics, Oxford Applied Mathematics and Computing Science Series, Oxford University Press, ISBN 978-0-19-859679-0 Batchelor, G. K. (1967), An Introduction to Fluid Dynamics, Cambridge University Press, ISBN 978-0-521-66396-0 Currie, I. G. (1974), Fundamental Mechanics of Fluids, McGraw-Hill, ISBN 978-0-07-015000-3 V. Girault and P. A. Raviart. Finite Element Methods for Navier–Stokes Equations: Theory and Algorithms. Springer Series in Computational Mathematics. Springer-Verlag, 1986 Landau, L. D.; Lifshitz, E. M. (1987), Fluid mechanics, vol. Course of Theoretical Physics Volume 6 (2nd revised ed.), Pergamon Press, ISBN 978-0-08-033932-0, OCLC 15017127 Polyanin, A. D.; Kutepov, A. M.; Vyazmin, A. V.; Kazenin, D. A. (2002), Hydrodynamics, Mass and Heat Transfer in Chemical Engineering, Taylor & Francis, London, ISBN 978-0-415-27237-7 Rhyming, Inge L. (1991), Dynamique des fluides, Presses polytechniques et universitaires romandes Smits, Alexander J. (2014), A Physical Introduction to Fluid Mechanics, Wiley, ISBN 0-47-1253499 Temam, Roger (1984): Navier–Stokes Equations: Theory and Numerical Analysis, ACM Chelsea Publishing, ISBN 978-0-8218-2737-6 Milne-Thomson, L.M., C.B.E (1962), Theoretical Hydrodynamics, Macmillan & Company Limited Tartar, L (2006), An Introduction to Navier Stokes Equation and Oceanography, Springer ISBN 3-540-35743-2 Birkhoff, Garrett (1960), Hydrodynamics, Princeton University Press Campos, D.
The blue mackerel can be flighty and difficult to catch, especially in estuaries and harbors. Blue mackerel are caught for both commercial and private use, for food as well as bait for tuna and other fish. Blue mackerel are often used as cat food, but are also consumed by humans smoked, grilled, or broiled. While easy to fillet and skin, they are difficult to debone, and care must be taken to avoid damaging their soft flesh. Blue mackerel are also commonly used as meat binders. After being freeze-dried, the protein is extracted and put into other meat products to keep the meat and seasonings bound tightly together, allowing costs to be lowered and enhancing the flavor and texture of the product.
Language enhancements (including NULL, abstract classes and methods, covariants and finals, closures in tags, and more) Asynchronous programming, using Futures Command line REPL Auto lockdown capability Distributed cache support (Redis, memcached, JCS) REST playground capability Modernized Admin UI Performance Monitoring Toolset
===== Rpn10 ===== Rpn10 was the first ubiquitin receptor identified on the proteasome. Rpn10 has a von Willebrand factor type A (VWA) attached to either a single Ubiquitin Interaction Motif (UIM), in yeast, or two UIMs in higher eukaryotes. The VWA domain binds between the base subcomplex and lid subcomplex of the 19S RP, while the UIM extends into a space over the AAA motor, though the UIM has not been seen in cryo-EM structures. NMR studies have shown that the UIM of Rpn10 binds mono-ubiquitin, and K48 di-ubiquitin with higher affinity. More recently, the C-terminus of Rpn10 in higher eukaryotes has been shown to bind an E3 ligase, UBE3A/E6AP (see Proteasomal Ligases).
=== Monster Energy v. Vital Pharmaceuticals Inc. === Monster Energy v. Vital Pharmaceuticals Inc. was a case brought by Monster Energy against Vital Pharmaceuticals Inc. (VPX) in 2018 alleging false advertising as well as theft of trade secrets. The matter concluded with a jury verdict in favor of the Monster Energy. Vital Pharmaceuticals produced Bang Energy, a competitor to Monster Energy. Monster Energy sued VPX over Bang Energy's "super creatine" branding. The case number was No. 5:18-cv-01882 at the U.S. District Court for Central District of California. Monster brought several claims against VPX, which included "unfair competition, trade libel, intentional interference with prospective economic advantage, conversion, false patent marketing, and violation of several anti-competitive laws." Regarding the false advertising claim, Monster Energy claimed that Bang Energy drinks were falsely advertised to have the ability to build muscles as well as improve brain functions. Monster Energy claimed that VPX falsely promised Bang’s "Super Creatine" ingredient to "fight depression and reverse ‘mental retardation.'" Monster further claimed that VPX violated U.S. Food and Drug Administration (FDA) regulations by making “unauthorized health claims.” Additionally, Monster claimed that VPX stole information from its competitors. Monster alleged that its own employees were poached by VPX and were promised high income and employment if they brought proprietary information from Monster.
Sources: en.wikipedia.org
During this meeting, he asked what Weizmann's objections had been to the 1903 Uganda Scheme that Herzl had supported to provide a portion of British East Africa to the Jewish people as a homeland. The scheme, which had been proposed to Herzl by Joseph Chamberlain, Colonial Secretary in Balfour's Cabinet, following his trip to East Africa earlier in the year, had been subsequently voted down following Herzl's death by the Seventh Zionist Congress in 1905 after two years of heated debate in the Zionist Organization. Weizmann responded that he believed the English are to London as the Jews are to Jerusalem. In January 1914, Weizmann first met Baron Edmond de Rothschild, a member of the French branch of the Rothschild family and a leading proponent of the Zionist movement, in relation to a project to build a Hebrew university in Jerusalem. The Baron was not part of the World Zionist Organization, but had funded the Jewish agricultural colonies of the First Aliyah and transferred them to the Jewish Colonization Association in 1899. This connection was to bear fruit later that year when the Baron's son, James de Rothschild, requested a meeting with Weizmann on 25 November 1914, to enlist him in influencing those deemed to be receptive within the British government to the Zionist agenda in Palestine. Through James's wife Dorothy, Weizmann was to meet Rózsika Rothschild, who introduced him to the English branch of the family – in particular her husband Charles and his older brother Walter, a zoologist and former Member of Parliament (MP).
== Biological properties == Ionophores are widely used in cell physiology experiments and biotechnology as these compounds can effectively perturb gradients of ions across biological membranes and thus they can modulate or enhance the role of key ions in the cell. Many ionophores have shown antibacterial and antifungal activities. Some of them also act against insects, pests and parasites. Some ionophores have been introduced into medicinal products for dermatological and veterinary use. A large amount of research has been directed toward investigating novel antiviral, anti-inflammatory, anti-tumor, antioxidant and neuroprotective properties of different ionophores. Chloroquine is an antimalarial and antiamebic drug. It is also used in the management of rheumatoid arthritis and lupus erythematosus. Pyrithione is used as an anti-dandruff agent in medicated shampoos for seborrheic dermatitis. It also serves as an anti-fouling agent in paints to cover and protect surfaces against mildew and algae. Clioquinol and PBT2 are 8-hydroxyquinoline derivatives. Clioquinol has antiprotozoal and topical antifungal properties, however its use as an antiprotozoal agent has widely restricted because of neurotoxic concerns. Clioquinol and PBT2 are currently being studied for neurodegenerative diseases, such as Alzheimer's disease, Huntington's disease and Parkinson's disease. Gramicidin is used in throat lozenges and has been used to treat infected wounds. Epigallocatechin gallate is used in many dietary supplements and has shown slight cholesterol-lowering effects.
Andy Street, the Mayor of the West Midlands, announces that he and his Manchester counterpart, Andy Burnham, are to meet Mark Harper, the Secretary of State for Transport, to discuss proposals for a privately funded alternative to the abandoned Manchester leg of HS2. The UK is to lend several pieces of the Ghana crown jewels back to Ghana 150 years after looting them from the court of the Asante king. 25 January The UK government announces fresh plans to ban the sale of zombie knives, with legislation taking effect from the autumn. Lloyds Banking Group announces plans to cut around 1,600 positions from its branch staff in a reorganisation that it says is because more customers are banking online. 26 January Buckingham Palace confirms that King Charles III has been admitted to hospital for treatment for an enlarged prostate. Jürgen Klopp, currently the longest-serving manager in the Premier League, announces he is departing as manager of Liverpool F.C. after the conclusion of the 2023–24 season, and taking a break from football management. 27 January The UK government suspends funding for the UN agency for Palestinian refugees, UNRWA, after the organisation sacked several officials reported to have been involved in the 7 October attacks on Israel. Kemi Badenoch, the business secretary, asks Henry Staunton to step down as chair of Post Office Limited after 13 months in the role, as the government moves to strengthen governance at the Post Office in the wake of the long-running Horizon IT scandal.
=== Fish === The epidermis of fish and of most amphibians consists entirely of live cells, with only minimal quantities of keratin in the cells of the superficial layer. It is generally permeable, and in the case of many amphibians, may actually be a major respiratory organ. The dermis of bony fish typically contains relatively little of the connective tissue found in tetrapods. Instead, in most species, it is largely replaced by solid, protective bony scales. Apart from some particularly large dermal bones that form parts of the skull, these scales are lost in tetrapods, although many reptiles do have scales of a different kind, as do pangolins. Cartilaginous fish have numerous tooth-like denticles embedded in their skin, in place of true scales. Sweat glands and sebaceous glands are both unique to mammals, but other types of skin gland are found in other vertebrates. Fish typically have a numerous individual mucus-secreting skin cells that aid in insulation and protection, but may also have poison glands, photophores, or cells that produce a more watery, serous fluid. In amphibians, the mucous cells are gathered together to form sac-like glands. Most living amphibians also possess granular glands in the skin, that secrete irritating or toxic compounds. Although melanin is found in the skin of many species, in the reptiles, the amphibians, and fish, the epidermis is often relatively colorless. Instead, the color of the skin is largely due to chromatophores in the dermis, which, in addition to melanin, may contain guanine or carotenoid pigments.
Sources: en.wikipedia.org
The Indian Ministry of External Affairs released its statement after much media attention, the statement said, "The Government of India's stated position on the United Nations Convention on the Law of the Sea is that the Convention does not authorize other States to carry out in the Exclusive Economic Zone and on the continental shelf, military exercises or maneuvers, in particular those involving the use of weapons or explosives, without the consent of the coastal state", it further added, "The USS John Paul Jones was continuously monitored transiting from the Persian Gulf towards the Malacca Straits. We have conveyed our concerns regarding this passage through our EEZ to the Government of USA through diplomatic channels." Former Chief of Naval Staff of the Indian Navy, Admiral Arun Prakash, commented on the event by tweeting "There is irony here. While India ratified [the] UN Law of the Seas in 1995, the US has failed to do it so far. For the 7th Fleet to carry out FoN missions in Indian EEZ in violation of our domestic law is bad enough. But publicizing it? USN please switch on IFF!". He further tweeted, "FoN ops by USN ships (ineffective as they may be) in South China Sea, are meant to convey a message to China that the putative EEZ around the artificial SCS islands is an 'excessive maritime claim.' But what is the 7th Fleet message for India?"
The four substrates of this enzyme are piceol (4-hydroxyacetophenone), reduced nicotinamide adenine dinucleotide phosphate (NADPH), oxygen, and a proton. Its products are hydroquinone monoacetate, oxidised NADP+, and water. This enzyme is a flavoprotein of Baeyer-Villiger monooxygenase type, which uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is (4-hydroxyphenyl)ethan-1-one,NADPH:oxygen oxidoreductase (ester-forming). This enzyme is also called HAPMO. It participates in bisphenol a degradation.
==== Dame Commander of the Order of the British Empire (DBE) ==== Civil Division Rachael Mary Dyche, . For political service. Deirdre Joan Hine, Chief Medical Officer, Welsh Office. For services to Medicine. Barbara Jean Lyon Mills, , Director of Public Prosecutions. Bridget Margaret Ogilvie, Director, Wellcome Trust. For services to Science. Diplomatic Service and Overseas List The Honourable Rosanna Wong Yick-ming, . For public and community service, Hong Kong.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.